Skip to content

Vesalius Therapeutics is a company pioneering a radical approach to common disease drug development. Its precision platform, Continuum Discovery™, integrates AI/ML analysis of human phenotypic data with human genetics and proprietary human-based experimental models to develop transformational therapies for patients suffering from common illnesses. The platform defines causal disease phenotypes linked to multigene circuits and unique points of intervention that drive rapid development of differentiated therapies. Combined with gene circuit-derived biomarkers and human-based translational models, Vesalius’ Continuum Discovery™ platform delivers efficient translation into smaller, shorter clinical trials with a higher probability of success. Vesalius was founded in 2019 by Flagship Pioneering. For more information visit, or follow us on Twitter and LinkedIn.

Latest News from Vesalius Therapeutics